Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    NCT04301518
Previous Study | Return to List | Next Study

Prematurity Risk Assessment Combined With Clinical Interventions for Improving Neonatal outcoMEs (PRIME)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04301518
Recruitment Status : Recruiting
First Posted : March 10, 2020
Last Update Posted : July 22, 2021
Sponsor:
Collaborator:
High Risk Pregnancy Center, Las Vegas, Nevada
Information provided by (Responsible Party):
Sera Prognostics, Inc.

Brief Summary:
This prospective, randomized, controlled study evaluates the safety and efficacy of a preterm birth (PTB) prevention strategy versus standard of care pregnancy management to reduce the incidence of adverse pregnancy outcomes.

Condition or disease Intervention/treatment Phase
Preterm Labor Preterm Birth Other: Multimodal intervention strategy Not Applicable

Detailed Description:

Prospective subjects will be randomized to the PTB prevention strategy (PTB Prevention arm) or to standard of care management (Control arm). Subjects randomized to the preterm birth prevention strategy will receive either routine standard of care pregnancy management or a multimodal intervention protocol reserved for higher risk pregnancies based on the results of a commercially-available laboratory developed test, PreTRM® (Sera Prognostics, Inc). The intervention protocol utilizes well-established high-risk pregnancy interventions to improve maternal and neonatal health outcomes.

After enrollment, all subjects will have a blood sample collected once between 19 1/7 weeks and 20 6/7 weeks (134-146 days) of pregnancy. Subjects will be randomized 1:1 to participate in the preterm birth prevention strategy arm or standard of care for pregnancy (Control) arm. Subjects randomized to the Control arm will not receive PreTRM® test results. Subjects randomized to the PTB Prevention arm will receive the results of the PreTRM® test. Results will be reported to the subject, the study Investigator, and the subject's primary pregnancy care provider as "higher risk" of prematurity (≥15%) or "not higher" risk. Subjects with results less than 15% risk (Not Higher Risk Group) by the PreTRM® test will receive standard of care for the duration of pregnancy through hospital discharge. Subjects with results at 15% risk of preterm delivery or greater (Higher Risk Group, equivalent to 2.0-fold the general population risk) by the PreTRM® test will complete a second consenting process to receive a prespecified intervention protocol directed toward reducing risk of adverse pregnancy outcomes inclusive of neonatal morbidity and mortality. All subjects will be followed through the duration of the pregnancy and delivery, and their neonates until initial hospital discharge to assess the course of pregnancy, labor, and any related maternal or fetal complications.

Birth outcomes will be obtained, and liveborn neonates followed through hospital discharge. Readmission of infants will be assessed at 180 days, 1 year and 3 years of life using the HealthCore Integrated Research Database to evaluate longer-term outcomes and costs associated with preterm delivery.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 6500 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: To determine the efficacy and safety of a PTB prevention strategy, this study will utilize PreTRM® to prospectively stratify pregnant women with a singleton gestation into categories of risk of PTB and adverse neonatal outcomes. Subjects randomized into the PTB Prevention arm who score at or above the predetermined threshold risk will receive protocol-specified care for the prevention of PTB throughout gestation utilizing defined interventions.
Masking: None (Open Label)
Primary Purpose: Prevention
Official Title: Prematurity Risk Assessment Combined With Clinical Interventions for Improving Neonatal outcoMEs
Actual Study Start Date : November 6, 2020
Estimated Primary Completion Date : September 30, 2022
Estimated Study Completion Date : June 30, 2025

Arm Intervention/treatment
Experimental: PTB Prevention
Approximately 6500 women will be screened, consented, and have the PreTRM® test sample collected. Randomization will occur 1:1 at each site. Those randomized to the PTB Prevention arm will receive the PreTRM® test results. If high risk, women will be consented to take part in the intervention. Those not higher risk will continue on with standard of care.
Other: Multimodal intervention strategy
  • Once weekly nurse support
  • 200 mg/daily micronized progesterone as vaginal suppository
  • 81 mg/daily low dose aspirin
  • two transvaginal ultrasounds
  • cerclage placement if cervical length is less than or equal to 10 mm prior to 24 weeks gestation

No Intervention: Control
Approximately 6500 women will be screened, consented, and have the PreTRM® test sample collected. Randomization will occur 1:1 at each site. Those randomized to the Control arm will not receive the PreTRM® test results. Control arm subjects will continue on with standard of care.



Primary Outcome Measures :
  1. Neonatal morbidity/mortality [ Time Frame: Through initial neonate discharge from hospital after birth for all neonates, assessed up to 180 days. ]
    Reduction in composite neonatal morbidity and mortality in the PTB Prevention arm versus the Control arm.

  2. Length of neonatal hospital stay [ Time Frame: Through initial neonate discharge from hospital after birth for all neonates, assessed up to 180 days. ]
    Reduction in length of neonatal hospital stay for admissions from time of birth up to initial neonatal hospital discharge home or neonatal death, whichever occurs first, in the PTB Prevention arm versus the Control arm.


Secondary Outcome Measures :
  1. Length of NICU hospital stay for neonates reduction [ Time Frame: Through initial neonate discharge from hospital after birth or until neonatal death, whichever occurs first, assessed up to 180 days. ]
    Reduction in all days spent in the neonatal intensive care unit (NICU) for neonates from time of birth up to discharge home or neonatal death, whichever occurs first, in the PTB Prevention arm versus the Control arm.

  2. Increase gestation [ Time Frame: Gestational age at delivery ]
    Increase in duration of gestation in the PTB Prevention arm versus the Control arm.


Other Outcome Measures:
  1. Reduction in occurrence of one or more major neonatal morbidities [ Time Frame: 3 year infant follow-up ]
    Reduction in occurrence of one or more major neonatal morbidities (MNM) with high likelihood of major chronic illness - cystic periventricular leukomalacia, grade 3 and 4 intraventricular hemorrhage, grade 3 or higher retinopathy of prematurity and/or bronchopulmonary dysplasia - in the PTB Prevention arm versus the Control arm.

  2. Cost reduction of neonatal hospitalizations for all admissions [ Time Frame: Birth up to neonatal discharge, assessed up to 180 days ]
    Reduction in all-cause cost of neonatal hospitalizations for all admissions from time of birth up to neonatal discharge in the PTB Prevention arm versus the Control arm in the Anthem beneficiary subset of the study population.

  3. Cost reduction of neonatal hospitalizations for NICU admissions [ Time Frame: Birth up to neonatal discharge, assessed up to 180 days ]
    Reduction in all-cause cost of neonatal hospitalizations, for NICU admissions from time of birth up to neonatal discharge in the PTB Prevention arm versus the Control arm in the Anthem beneficiary subset of the study population.

  4. Cost reduction of neonatal hospitalizations for PTB admissions [ Time Frame: Birth up to neonatal discharge, assessed up to 180 days ]
    Reduction in all-cause cost of neonatal hospitalizations, for PTB admissions from time of birth up to neonatal discharge in the PTB Prevention arm versus the Control arm in the Anthem beneficiary subset of the study population.

  5. Cost reduction of neonatal hospitalizations for PTB admissions after sPTB [ Time Frame: Birth up to neonatal discharge, assessed up to 180 days ]
    Reduction in all-cause cost of neonatal hospitalizations from time of birth up to neonatal discharge for admissions of preterm births after spontaneous rupture of membranes or spontaneous onset of labor (sPTB), in the PTB Prevention arm versus the Control arm in the Anthem beneficiary subset of the study population.

  6. Reduction in rate of preterm birth <32 weeks gestation [ Time Frame: Delivery ]
    Reduction in the rate of preterm birth <32 weeks of gestation in the PTB Prevention arm versus the Control arm.

  7. Reduction in rate of preterm birth <35 weeks gestation [ Time Frame: Delivery ]
    Reduction in the rate of preterm birth <35 weeks of gestation in the PTB Prevention arm versus the Control arm

  8. Reduction in rate of preterm birth <37 weeks gestation [ Time Frame: Delivery ]
    Reduction in the rate of preterm birth <37 weeks of gestation in the PTB Prevention arm versus the Control arm.

  9. Reduction in rate of preterm birth <32 weeks gestation after sPTB [ Time Frame: Delivery ]
    Reduction in the rate of preterm birth <32 weeks of gestation after spontaneous rupture of membranes or spontaneous onset of labor (sPTB), in the PTB Prevention arm versus the Control arm.

  10. Reduction in rate of preterm birth <35 weeks gestation after sPTB [ Time Frame: Delivery ]
    Reduction in the rate of preterm birth <35 weeks of gestation after spontaneous rupture of membranes or spontaneous onset of labor (sPTB), in the PTB Prevention arm versus the Control arm.

  11. Reduction in rate of preterm birth <37 weeks gestation after sPTB [ Time Frame: Delivery ]
    Reduction in the rate of preterm birth <37 weeks of gestation after spontaneous rupture of membranes or spontaneous onset of labor (sPTB), in the PTB Prevention arm versus the Control arm.

  12. NICU days reduction/NICU admissions <37 weeks [ Time Frame: Through initial neonatal discharge from hospital after birth or until neonatal death, whichever occurs first, up to 180 days of life ]
    Reduction in all days spent in the NICU for all NICU admissions of preterm neonates (<37 weeks, only PTB with NICU admission) from birth up to neonatal discharge to home or neonatal death, whichever occurs first, in the PTB Prevention arm versus the Control arm.

  13. NICU days reduction/NICU admissions of sPTB neonates with NICU admission [ Time Frame: Through initial neonatal discharge from hospital after birth or until neonatal death, whichever occurs first, up to 180 days of life ]
    Reduction in all days spent in the NICU for all NICU admissions of spontaneous preterm neonates (only sPTB with NICU admission) from birth up to neonatal discharge to home or neonatal death, whichever occurs first, in the PTB Prevention arm versus the Control arm.

  14. NICU days reduction/NICU admissions of all preterm neonates [ Time Frame: Through initial neonatal discharge from hospital after birth or until neonatal death, whichever occurs first, up to 180 days of life ]
    Reduction in all days spent in the NICU from birth up to neonatal discharge to home or neonatal death, whichever occurs first, for all preterm neonates (independent of NICU admission including zero-length stays for those not admitted), in the PTB Prevention arm versus the Control arm.

  15. NICU days reduction/NICU admissions of sPTB neonates [ Time Frame: Through initial neonatal discharge from hospital after birth or until neonatal death, whichever occurs first, up to 180 days of life ]
    Reduction in all days spent in the NICU from birth up to neonatal discharge to home or neonatal death, whichever occurs first, for all sPTB neonates (independent of NICU admission including zero-length stays for those not admitted), in the PTB Prevention arm versus the Control arm.

  16. Preterm neonatal hospital stay reduction [ Time Frame: Through initial neonatal discharge from hospital after birth or until neonatal death, whichever occurs first, up to 180 days of life ]
    Reduction in length of neonatal hospital stay from birth up to neonatal discharge home or neonatal death, whichever occurs first, for all preterm neonates (<37 weeks, all PTB), in the PTB Prevention arm versus the Control arm.

  17. Preterm neonatal hospital stay reduction for sPTB [ Time Frame: Through initial neonatal discharge from hospital after birth or until neonatal death, whichever occurs first, up to 180 days of life ]
    Reduction in length of neonatal hospital stay from birth up to neonatal discharge home or neonatal death, whichever occurs first, for all preterm neonates (<37 weeks, all sPTB), in the PTB Prevention arm versus the Control arm.

  18. Neonatal hospital and NICU stay reduction after readmission for all admissions [ Time Frame: From initial neonatal discharge to home (assessed up to 180 days of life) and within 180 days of life for those discharged prior to 180 days of life ]
    Reduction in days of total hospital and NICU stay after readmission of infants after initial discharge home and within 180 days of life for all admissions, in the PTB Prevention arm versus the Control arm in the Anthem beneficiary subset of the study population.

  19. Neonatal hospital and NICU stay reduction after readmission for NICU admissions [ Time Frame: From initial neonatal discharge to home (assessed up to 180 days of life) and within 180 days of life for those discharged prior to 180 days of life ]
    Reduction in days of total hospital and NICU stay after readmission of infants after initial discharge home and within 180 days of life for NICU admissions, in the PTB Prevention arm versus the Control arm in the Anthem beneficiary subset of the study population.

  20. Neonatal hospital and NICU stay reduction after readmission for PTB admissions [ Time Frame: From initial neonatal discharge to home (assessed up to 180 days of life) and within 180 days of life for those discharged prior to 180 days of life ]
    Reduction in days of total hospital and NICU stay after readmission of infants after initial discharge home and within 180 days of life for PTB admissions, in the PTB Prevention arm versus the Control arm in the Anthem beneficiary subset of the study population.

  21. Neonatal hospital and NICU stay reduction after readmission for sPTB admissions [ Time Frame: From initial neonatal discharge to home (assessed up to 180 days of life) and within 180 days of life for those discharged prior to 180 days of life ]
    Reduction in days of total hospital and NICU stay after readmission of infants after initial discharge home and within 180 days of life for sPTB admissions, in the PTB Prevention arm versus the Control arm in the Anthem beneficiary subset of the study population.

  22. Hospital readmission cost reduction for all admissions [ Time Frame: From initial neonatal discharge to home (assessed up to 180 days of life) and within 180 days of life for those discharged prior to 180 days of life ]
    Reduction in all-cause costs of hospital readmission of infants after initial discharge and within 180 days of life for all admissions, in the PTB Prevention arm versus the Control arm in the Anthem beneficiary subset of the study population.

  23. Hospital readmission cost reduction for NICU admissions [ Time Frame: From initial neonatal discharge to home (assessed up to 180 days of life) and within 180 days of life for those discharged prior to 180 days of life ]
    Reduction in all-cause costs of hospital readmission of infants after initial discharge and within 180 days of life for NICU admissions, in the PTB Prevention arm versus the Control arm in the Anthem beneficiary subset of the study population.

  24. Hospital readmission cost reduction for PTB admissions [ Time Frame: From initial neonatal discharge to home (assessed up to 180 days of life) and within 180 days of life for those discharged prior to 180 days of life ]
    Reduction in all-cause costs of hospital readmission of infants after initial discharge and within 180 days of life for PTB admissions, in the PTB Prevention arm versus the Control arm in the Anthem beneficiary subset of the study population.

  25. Hospital readmission cost reduction for sPTB admissions [ Time Frame: From initial neonatal discharge to home (assessed up to 180 days of life) and within 180 days of life for those discharged prior to 180 days of life ]
    Reduction in all-cause costs of hospital readmission of infants after initial discharge and within 180 days of life for sPTB admissions, in the PTB Prevention arm versus the Control arm in the Anthem beneficiary subset of the study population.

  26. Hospital readmission cost reduction for all admissions within first year of life [ Time Frame: From initial neonatal discharge to home (assessed up to 180 days of life) and within first year of life ]
    Reduction in all-cause costs of hospital readmission of infants after initial discharge and within the first year of life for all admissions, in the PTB Prevention arm versus the Control arm in the Anthem beneficiary subset of the study population.

  27. Hospital readmission cost reduction within first year of life for NICU admissions [ Time Frame: From initial neonatal discharge to home (assessed up to 180 days of life) and within first year of life ]
    Reduction in all-cause costs of hospital readmission of infants after initial discharge and within the first year of life for NICU admissions, in the PTB Prevention arm versus the Control arm in the Anthem beneficiary subset of the study population.

  28. Hospital readmission cost reduction within first year of life for PTB admissions [ Time Frame: From initial neonatal discharge to home (assessed up to 180 days of life) and within first year of life ]
    Reduction in all-cause costs of hospital readmission of infants after initial discharge and within the first year of life for PTB admissions, in the PTB Prevention arm versus the Control arm in the Anthem beneficiary subset of the study population.

  29. Hospital readmission cost reduction within first year of life for sPTB admissions [ Time Frame: From initial neonatal discharge to home (assessed up to 180 days of life) and within first year of life ]
    Reduction in all-cause costs of hospital readmission of infants after initial discharge and within the first year of life for sPTB admissions, in the PTB Prevention arm versus the Control arm in the Anthem beneficiary subset of the study population.

  30. Hospital readmission cost reduction within first three years of life for all admissions [ Time Frame: From initial neonatal discharge to home (assessed up to 180 days of life) and within first three years of life ]
    Reduction in all-cause costs of hospital readmission of infants after initial discharge and within the first three years of life for all admissions, in the PTB Prevention arm versus the Control arm in the Anthem beneficiary subset of the study population.

  31. Hospital readmission cost reduction within first three years of life for NICU admissions [ Time Frame: From initial neonatal discharge to home (assessed up to 180 days of life) and within first three years of life ]
    Reduction in all-cause costs of hospital readmission of infants after initial discharge and within the first three years of life for NICU admissions, in the PTB Prevention arm versus the Control arm in the Anthem beneficiary subset of the study population.

  32. Hospital readmission cost reduction within first three years of life for PTB admissions [ Time Frame: From initial neonatal discharge to home (assessed up to 180 days of life) and within first three years of life ]
    Reduction in all-cause costs of hospital readmission of infants after initial discharge and within the first three years of life for PTB admissions, in the PTB Prevention arm versus the Control arm in the Anthem beneficiary subset of the study population.

  33. Hospital readmission cost reduction within first three years of life for sPTB admissions [ Time Frame: From initial neonatal discharge to home (assessed up to 180 days of life) and within first three years of life ]
    Reduction in all-cause costs of hospital readmission of infants after initial discharge and within the first three years of life for sPTB admissions, in the PTB Prevention arm versus the Control arm in the Anthem beneficiary subset of the study population.

  34. NICU admission rate reduction [ Time Frame: Through initial neonatal discharge from hospital after birth or until neonatal death, whichever occurs first, assessed up to 180 days ]
    Reduction in NICU admission rates in the immediate neonatal period prior to initial discharge home or neonatal death, whichever occurs first, in the PTB Prevention arm versus Control arm.

  35. Neonatal morbidity and mortality index observation [ Time Frame: Within one year of primary analysis ]
    Observation of the dependence of the composite neonatal morbidity and mortality index co-primary endpoint on severity of risk as defined by PreTRM® categorical test results and continuous risk score, both in comparison of the PTB Prevention arm versus the Control arm and with stratification of both arms by PreTRM® test result.

  36. Neonatal hospital length of stay observation [ Time Frame: Within one year of primary analysis ]
    Observation of the dependence of the length of neonatal hospital stay co-primary endpoint on severity of risk as defined by PreTRM® categorical test results and continuous risk score, both in comparison of the PTB Prevention arm versus the Control arm and with stratification of both arms by PreTRM® test result.

  37. NICU length of stay observation [ Time Frame: Within one year of primary analysis ]
    Observation of the dependence of the NICU length of stay secondary endpoint on severity of risk as defined by PreTRM® categorical test results and continuous risk score, both in comparison of the PTB Prevention arm versus the Control arm and with stratification of both arms by PreTRM® test result.

  38. Duration of gestation observation [ Time Frame: Within one year of primary analysis ]
    Observation of the dependence of the duration of gestation secondary endpoint on severity of risk as defined by PreTRM® categorical test results and continuous risk score, both in comparison of the PTB Prevention arm versus the Control arm and with stratification of both arms by PreTRM® test result.

  39. Major neonatal morbidities observation [ Time Frame: Within one year of primary analysis ]
    Observation of the dependence of the MNM exploratory endpoint on severity of risk as defined by PreTRM® categorical test results and continuous risk score, both in comparison of the PTB Prevention arm versus the Control arm and with stratification of both arms by PreTRM® test result.

  40. NICU length of stay amongst preterm neonates observation [ Time Frame: Within one year of primary analysis ]
    Observation of the dependence of the exploratory endpoint of dependence of NICU length of stay amongst preterm neonates on severity of risk as defined by PreTRM® categorical test results and continuous risk score, both in comparison of the PTB Prevention arm versus the Control arm and with stratification of both arms by PreTRM® test result.

  41. Hospital length of stay amongst preterm neonates observation [ Time Frame: Within one year of primary analysis ]
    Observation of the dependence of the exploratory endpoint of dependence of hospital length of stay amongst preterm neonates on severity of risk as defined by PreTRM® categorical test results and continuous risk score, both in comparison of the PTB Prevention arm versus the Control arm and with stratification of both arms by PreTRM® test result.

  42. Preterm birth rate observation [ Time Frame: Within one year of primary analysis ]
    Observation of the dependence of the preterm birth rate exploratory endpoint on severity of risk as defined by PreTRM® categorical test results and continuous risk score, both in comparison of the PTB Prevention arm versus the Control arm and with stratification of both arms by PreTRM® test result.

  43. Neonatal hospitalization cost observation [ Time Frame: Within one year of primary analysis ]
    Observation of the dependence of the exploratory endpoint of all-cause cost of neonatal hospitalization on severity of risk as defined by PreTRM® categorical test results and continuous risk score, both in comparison of the PTB Prevention arm versus the Control arm and with stratification of both arms by PreTRM® test result.

  44. Preterm neonatal hospitalization observation [ Time Frame: Within one year of primary analysis ]
    Observation of the dependence of the exploratory endpoint of all-cause cost of neonatal hospitalization amongst preterm neonates on severity of risk as defined by PreTRM® categorical test results and continuous risk score, both in comparison of the PTB Prevention arm versus the Control arm and with stratification of both arms by PreTRM® test result.

  45. Intervention protocol observation/neonatal morbidity and mortality index [ Time Frame: Within one year of primary analysis ]
    Observation of the contribution of components of the intervention protocol, including consideration of consent and adherence, to the co-primary endpoint of composite neonatal morbidity and mortality index.

  46. Intervention protocol observation/length of neonatal hospital stay [ Time Frame: Within one year of primary analysis ]
    Observation of the contribution of components of the intervention protocol, including consideration of consent and adherence, to the co-primary endpoint of length of neonatal hospital stay.

  47. Intervention protocol observation/length of NICU stay [ Time Frame: Within one year of primary analysis ]
    Observation of the contribution of components of the intervention protocol, including consideration of consent and adherence, to the, secondary endpoint of length of NICU stay.

  48. Intervention protocol observation/duration of gestation [ Time Frame: Within one year of primary analysis ]
    Observation of the contribution of components of the intervention protocol, including consideration of consent and adherence, to the secondary endpoint of duration of gestation.

  49. Intervention protocol observation/major neonatal morbidities [ Time Frame: Within one year of primary analysis ]
    Observation of the contribution of components of the intervention protocol, including consideration of consent and adherence, to the MNM and exploratory endpoint.

  50. Intervention protocol observation/length of NICU stay amongst preterm neonates [ Time Frame: Within one year of primary analysis ]
    Observation of the contribution of components of the intervention protocol, including consideration of consent and adherence, to the exploratory endpoint of length of NICU stay amongst preterm neonates.

  51. Intervention protocol observation/length of hospital stay amongst preterm neonates [ Time Frame: Within one year of primary analysis ]
    Observation of the contribution of components of the intervention protocol, including consideration of consent and adherence, to the exploratory endpoint of length of hospital stay amongst preterm neonates.

  52. Intervention protocol observation/preterm birth rate [ Time Frame: Within one year of primary analysis ]
    Observation of the contribution of components of the intervention protocol, including consideration of consent and adherence, to the exploratory endpoint of preterm birth rate.

  53. Intervention protocol observation/neonatal hospitalization [ Time Frame: Within one year of primary analysis ]
    Observation of the contribution of components of the intervention protocol, including consideration of consent and adherence, to the exploratory endpoint of all-cause cost of neonatal hospitalization.

  54. Intervention protocol observation/neonatal hospitalization amongst preterm neonates [ Time Frame: Within one year of primary analysis ]
    Observation of the contribution of components of the intervention protocol, including consideration of consent and adherence, to the exploratory endpoint of all-cause cost of neonatal hospitalization amongst preterm neonates.

  55. COVID-19 primary [ Time Frame: Within one year of primary analysis ]
    Observation of the effect on primary endpoints of SARS-CoV-2 positivity or COVID-19 salient symptoms requiring evaluation in an ER or hospital setting after enrollment.

  56. COVID-19 secondary [ Time Frame: Within one year of primary analysis ]
    Observation of the effect on secondary endpoints of SARS-CoV-2 positivity or COVID-19 salient symptoms requiring evaluation in an ER or hospital setting after enrollment.

  57. COVID-19 exploratory [ Time Frame: Within one year of primary analysis ]
    Observation of the effect on exploratory endpoints of SARS-CoV-2 positivity or COVID-19 salient symptoms requiring evaluation in an ER or hospital setting after enrollment.

  58. Anxiety - Generalized Anxiety Disorder 7-item (GAD-7) [ Time Frame: Within one year of primary analysis ]
    Change (mean difference) in Generalized Anxiety Disorder 7-item (GAD-7) scores at enrollment and 6-weeks post-enrollment in a subset of subjects. Scale range 0 - 21, higher values correlate with higher anxiety

  59. Anxiety - Perinatal Anxiety Screening Scale (PASS) [ Time Frame: Within one year of primary analysis ]
    Change (mean difference) in perinatal Anxiety Screening Scale (PASS) scores at enrollment and 6-weeks post-enrollment in a subset of subjects. Scale range 0 - 93, higher values correlate with higher anxiety



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Gender Based Eligibility:   Yes
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria

  1. Subject is 18 years of age or older
  2. Subject is willing and able to provide informed consent and comply with intervention if applicable
  3. Subject gestational age is currently within 19 1/7 and 20 6/7 weeks using best estimated due date
  4. This is a singleton intrauterine pregnancy
  5. Subject has no signs and/or symptoms of preterm labor and has intact membranes
  6. Subject has had a 2nd trimester anatomic ultrasound, including evaluation of cervical length, completed by the date of enrollment, but no earlier than 18
  7. In the opinion of the Investigator, the subject's delivery data will be accessible within 20 business days from delivery, and neonatal data will be available for data collection purposes within 20 business days from discharge

Exclusion Criteria:

  1. Subject has had a prior spontaneous preterm delivery (gestational age at birth less than 37 0/7 weeks gestation)
  2. Subject has cervical length less than 25 millimeters (mm) on 2nd trimester transvaginal ultrasound at time of enrollment
  3. Subject has taken progesterone or progesterone-derivative medication after 13 6/7 weeks gestation
  4. Singleton gestation reduced from an original multiple gestation via embryonic reduction or vanishing twin
  5. There is a known major fetal anomaly or chromosomal/ genetic abnormality
  6. Placenta accreta spectrum disorder (accreta/ increta/ percreta)
  7. Placenta covers the internal os by more than 2.5 centimeters (cm) at time of 2nd trimester anatomic ultrasound (18 0/7 and 20 6/7 weeks gestation)
  8. The subject has experienced vaginal bleeding after 13 6/7 weeks gestation
  9. One or more of the following uterine risk factors are present: fibroids > 5.0cm, uterine malformation, history of classical cesarean section, history of prior uterine surgery with trans-myometrial penetration (excludes low transverse cesarean section)
  10. The subject has a planned cesarean section or induction of labor prior to 370/7 weeks gestation
  11. The subject had a cerclage or pessary placed prior to enrollment window in the current pregnancy
  12. The subject has received enoxaparin, heparin, heparin sodium or other low molecular weight heparin since last menstrual period
  13. Subject has current diagnosis of polyhydramnios
  14. Subject has known use of illicit drugs in the current pregnancy, including cocaine, methamphetamine, and/or opioid use disorder in the current pregnancy
  15. Subject is allergic to aspirin or has experienced gastrointestinal bleeding associated with use
  16. Subject is allergic to peanuts and/or peanut oil used in exogenous progesterone formulation
  17. Subject is participating in any other interventional research studies during the current pregnancy
  18. Subject has tested positive for COVID-19 via an U.S. Food and Drug Administration (FDA)-authorized diagnostic test for SARS-CoV-2 after last menstrual period (LMP) date
  19. Subject has been evaluated for COVID-19 salient symptoms per the American College of Obstetrics and Gynecology/ Society for Maternal Fetal Medicine (ACOG/SMFM) "Outpatient Assessment and Management for Pregnant Women with Suspected or Confirmed Novel Coronavirus (COVID-19)" in an emergency room (ER) or hospital setting since the last menstrual period (LMP) date.
  20. Subject has a chronic medical disease(s) which require intensive medical surveillance and may increase the risk of preterm delivery to include:

    • Lupus
    • Chronic lung diseases on oxygen replacement
    • Cardiac disease with high risk of maternal mortality, including Marfan syndrome with dilated aortic root and significant pulmonary hypertension
    • Neuromuscular diseases at risk for pulmonary insufficiency (e.g. myotonic dystrophy)
    • Renal failure on dialysis
    • Uncontrolled or poorly controlled hyperthyroidism

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04301518


Contacts
Layout table for location contacts
Contact: Ashley Magnavita, MPH 617-972-3182 amagnavita@healthcore.com
Contact: Alissa Mooney amooney@healthcore.com

Locations
Layout table for location information
United States, Kentucky
University of Kentucky Healthcare Recruiting
Lexington, Kentucky, United States, 40536
Contact: Cynthia Cockerham-Morris, BSN, BS    859-629-2015    ctcock2@uky.edu   
Principal Investigator: John O'Brien, MD         
United States, Nevada
High Risk Pregnancy Center Recruiting
Las Vegas, Nevada, United States, 89106
Contact: Jennifer Somdahl, RN    702-382-3200    jsomdahl@hrpregnancy.com   
Principal Investigator: Brian Iriye, MD         
United States, Virginia
University of Virginia Recruiting
Charlottesville, Virginia, United States, 22908
Contact: Christopher Ennen, MD    434-924-2500    CE4JD@hscmail.mcc.virginia.edu   
Contact: Amanda Urban, MS    434-409-3100    AJR5Y@hscmail.mcc.virginia.edu   
Sub-Investigator: Donald Dudley, MD         
Sponsors and Collaborators
Sera Prognostics, Inc.
High Risk Pregnancy Center, Las Vegas, Nevada
Investigators
Layout table for investigator information
Principal Investigator: Brian Iriye, MD High Risk Pregnancy Center
Layout table for additonal information
Responsible Party: Sera Prognostics, Inc.
ClinicalTrials.gov Identifier: NCT04301518    
Other Study ID Numbers: SP019
First Posted: March 10, 2020    Key Record Dates
Last Update Posted: July 22, 2021
Last Verified: April 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Sera Prognostics, Inc.:
neonate
NICU
neonatal
preterm
Additional relevant MeSH terms:
Layout table for MeSH terms
Premature Birth
Obstetric Labor, Premature
Obstetric Labor Complications
Pregnancy Complications